Transcatheter aortic valve implantation has expanded to low-risk and asymptomatic patients with aortic stenosis, shifting focus to lifetime management, valve durability, and future coronary access.
TAVI has evolved from a treatment for prohibitive surgical risk patients to the standard of care for a broader population, with future focus on lifetime management and expanded indications.
The advent of transcatheter aortic valve implantation (TAVI) has redefined the treatment of aortic stenosis over the last two decades, evolving from a therapy reserved for patients that were deemed to be of prohibitive surgical risk to the standard of care for a large group of patients presenting with symptomatic disease. With improvements in technology, operator and institutional experience and longer-term outcome data, recent guidelines have supported the broadening of indications to low-risk and asymptomatic patients in addition to other pathologies including the management of failed surgical bioprosthetic valves and aortic regurgitation. The rapid developments in the field have resulted in a rapid expansion of TAVI. The focus has moved from the technical aspects of the procedure itself that are now well established to the lifetime management of patients with aortic stenosis, particularly younger patients with regard to valve durability, planning for a further intervention after TAVI and associated considerations including future coronary access. Beyond aortic stenosis, TAVI technology is also increasingly being utilized for the management of failed surgical bioprostheses, bicuspid valve disease, aortic incompetence and mitral/tricuspid disease and these represent future areas of focus in the field.
Karameh et al. (Tue,) conducted a review in Aortic stenosis. Transcatheter Aortic Valve Implantation (TAVI) was evaluated. Transcatheter aortic valve implantation has expanded to low-risk and asymptomatic patients with aortic stenosis, shifting focus to lifetime management, valve durability, and future coronary access.